Pre-exposure prophylaxis is cost-effective for HIV in the UK

Lancet Infect Dis. 2018 Jan;18(1):10-11. doi: 10.1016/S1473-3099(17)30594-7. Epub 2017 Oct 17.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anti-HIV Agents / economics*
  • Cost-Benefit Analysis
  • HIV
  • HIV Infections*
  • Homosexuality, Male
  • Humans
  • Male
  • Pre-Exposure Prophylaxis / economics*
  • Sexual and Gender Minorities*
  • United Kingdom

Substances

  • Anti-HIV Agents